Đánh giá kết quả điều trị tân bổ trợ ung thư vú tại Bệnh viện ung bướu Đà Nẵng

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thanh Tinh Bui, Trung Quan Le, Xuan Quang Nguyen, Thanh Hai Pham

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Journal of Clinical Medicine – Hue Central Hospital, 2020

Mô tả vật lý: tr.96-101

Bộ sưu tập: Metadata

ID: 379309

Thêm vào giỏ Liên kết toàn văn

Hóa trị tân bổ trợ ung thư vú giúp giảm giai đoạn bướu tại chỗ, giảm độ rộng phẫu thuật. Cải thiện sống còn khi đạt được đáp ứng bệnh học hoàn toàn (pCR). Đối tượng và phương pháp nghiên cứu: Nghiên cứu hồi cứu mô tả, cắt ngang. Tiêu chuẩn chọn bệnh: BN UTV giai đoạn T2-4,N0-3,M0 được hóa trị tân bổ trợ. Loại trừ các trường hợp ung thư vú tại chỗ hoặc đã điều trị trước đó. Kết quả: Độ tuổi trung bình là 48, kích thước bướu trung bình 6.0 cm, Đa số là carcinoma ống tuyến vú dạng NOS (97,8%) và grad 2 (85,6%). Nội tiết dương tính trong 57%, HER-2 dương tính trong 38,7% và có 18,3% nhóm tam âm. Phác đồ kết hợp anthacycline và Taxane chiếm 94,7%, phác đồ có Trastuzumab chiếm 25% trong nhóm Her2 (+). Có 8,3% bệnh tiến triển trong khi hóa trị. Về phẫu thuật: Phẫu thuật bảo tồn chiếm (20,5%), Tạo hình vú tức thì chiếm 6,8%, Đoạn nhũ toàn bộ chiếm 71,6%. Có 4,3% được phẫu thuật sinh thiết hạch gác. Tình trạng Her2 khác biệt có ý nghĩa thống kê giữa 2 nhóm đạt và không đạt pCR. Nhóm nội tiết âm tính, Ki67 cao và nhóm tam âm có tỷ lệ đạt pCR cao hơn nhưng không có ý nghĩa thống kê. Kết luận: Hóa trị tân bổ trợ giúp giảm giai đoạn tại chỗ, tăng tỷ lệ phẫu thuật bảo tồn và tạo hình vú. Tình trạng Her2 có mối tương quan với tỷ lệ đạt đáp ứng bệnh học hoàn toàn (pCR).Neoadjuvant chemotherapy for breast cancer was used to downstaging tumours to facilitate breast-conserving surgery.Methods: A descriptive retrospective study of 93 breast cancer patients at Da Nang Oncology Hospitalfrom January 2017 to December 2019. Patients diagnosed with locally advanced breast cancer cT2-4N0-3M0. Exclude cases of Ductal carcinoma in situ from breast or previously treated.Results: an average age of 48, an average tumor size of 6.0 cm, the majority were Invasive ductal carci- noma (97.8%) and grade 2 ( 85.6%). Hormon receptor positive in 57%, HER-2 positive in 38.7% and 18.3%triple negative Breast cancer. The combination chemotherapy regimen Anthacycline and Taxane accounted for 94.7%, Trastuzumab-based regimen accounted for 25%. There was 8.3% progression of disease duringneoadjuvant chemotherapy. About Surgery: Breast- conserving surgery in 20.5%, Breast reconstruction in6.8%, Mastectomy in 71.6%, Sentinel lymph node biopsy in 4.3%. Her2 status was significantly differentbetween the groups with and without pCR.. Endocrine receptors are negative, Ki67 is high, and Triple nega- tive has a higher rate of pCR but not statistically significant.Conclusion: Neoadjuvant chemotherapy helps to downstaging tumours to facilitate breast-conservingsurgery. Her2 status is correlated with the rate of complete pathological response (pCR).

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR